Annexin Pharmaceuticals AB
Annexin Pharmaceuticals AB (publ), a clinical stage biotechnology company, develops drug candidates for the treatment of various cardiovascular diseases. It develops ANXV, a human recombinant protein and Annexin A5, natural protein that protects and repairs cells, as well as counteract unwanted inflammatory and immune cell reactions. Annexin Pharmaceuticals AB (publ) was incorporated in 2014 and … Read more
Annexin Pharmaceuticals AB (ANNX) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of December 2025: -0.380x
Based on the latest financial reports, Annexin Pharmaceuticals AB (ANNX) has a cash flow conversion efficiency ratio of -0.380x as of December 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-9.48 Million) by net assets (Skr24.93 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Annexin Pharmaceuticals AB - Cash Flow Conversion Efficiency Trend (2015–2025)
This chart illustrates how Annexin Pharmaceuticals AB's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Annexin Pharmaceuticals AB Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Annexin Pharmaceuticals AB ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
BRITANNIA LIFE SCIENCES
F:L020
|
N/A |
|
Teera-Mongkol Industry Public Company Limited
BK:TMI
|
0.096x |
|
Pharmsville Co. Ltd
KQ:318010
|
0.004x |
|
Orpheus Uranium Ltd
AU:ORP
|
-0.119x |
|
TZ Ltd
AU:TZL
|
0.218x |
|
Nyesa Valores Corp SA
MC:NYE
|
-0.331x |
|
Utility Business Alliance PCL
BK:UBA
|
0.014x |
|
eEducation Albert AB
ST:ALBERT
|
-0.185x |
Annual Cash Flow Conversion Efficiency for Annexin Pharmaceuticals AB (2015–2025)
The table below shows the annual cash flow conversion efficiency of Annexin Pharmaceuticals AB from 2015 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | Skr24.93 Million | Skr-36.92 Million | -1.481x | +59.57% |
| 2024-12-31 | Skr13.71 Million | Skr-50.23 Million | -3.663x | -58.77% |
| 2023-12-31 | Skr18.81 Million | Skr-43.40 Million | -2.307x | -68.98% |
| 2022-12-31 | Skr30.15 Million | Skr-41.16 Million | -1.365x | -41.68% |
| 2021-12-31 | Skr46.73 Million | Skr-45.02 Million | -0.964x | +49.27% |
| 2020-12-31 | Skr20.64 Million | Skr-39.20 Million | -1.899x | +15.17% |
| 2019-12-31 | Skr11.49 Million | Skr-25.73 Million | -2.239x | -213.04% |
| 2018-12-31 | Skr39.85 Million | Skr-28.50 Million | -0.715x | +55.27% |
| 2017-12-31 | Skr24.44 Million | Skr-39.08 Million | -1.599x | -150.32% |
| 2016-12-31 | Skr15.57 Million | Skr-9.95 Million | -0.639x | -101.75% |
| 2015-12-31 | Skr-137.00K | Skr-5.01 Million | 36.584x | -- |